Discovery of Aminopyrazole Derivatives as Potent Inhibitors of Wild-Type and Gatekeeper Mutant FGFR2 and 3

[Image: see text] Fibroblast growth factor receptors (FGFR) 2 and 3 have been established as drivers of numerous types of cancer with multiple drugs approved or entering late stage clinical trials. A limitation of current inhibitors is vulnerability to gatekeeper resistance mutations. Using a combin...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:ACS Med Chem Lett
Asıl Yazarlar: Brawn, Ryan A., Cook, Andrew, Omoto, Kiyoyuki, Ke, Jiyuan, Karr, Craig, Colombo, Federico, Virrankoski, Milena, Prajapati, Sudeep, Reynolds, Dominic, Bolduc, David M., Nguyen, Tuong-Vi, Gee, Patricia, Borrelli, Deanna, Caleb, Benjamin, Yao, Shihua, Irwin, Sean, Larsen, Nicholas A., Selvaraj, Anand, Zhao, Xuesong, Ioannidis, Stephanos
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Chemical Society 2020
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7812672/
https://ncbi.nlm.nih.gov/pubmed/33488969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acsmedchemlett.0c00517
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller